T-cell-engaging bispecific antibodies (BsAbs) simultaneously bind to antigens on tumour
cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T …

Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is
accelerating. This analysis summarizes the data derived from the clinical trials conducted at …

Blinatumomab is a bispecific T cell engager that has shown efficacy in relapsed/refractory
Philadelphia chromosome (Ph)-positive and Ph-negative acute lymphoblastic leukemia …

Blinatumomab is a bispecific T-cell engager approved for B-cell precursor acute
lymphoblastic leukemia (B-ALL) with persistent minimal residual disease (MRD) or in …

Pediatric-inspired chemotherapy is the standard of care for younger adults with Philadelphia
chromosome–negative acute lymphoblastic leukemia/lymphoma (Ph–ALL/LL). In LAL1913 …

Simple Summary Immunotherapy has improved the outcome of relapsed/refractory B-
lymphoblastic leukemia. However, little is known about the outcome after recurrence and re …

Abstract Experts from the European Leukemia Net (ELN) working group for adult acute
lymphoblastic leukemia have identified an unmet need for guidance regarding management …

This narrative review seeks to summarize chemotherapeutic regimens commonly used for
patients with newly diagnosed Philadelphia (Ph) chromosome–negative B-cell precursor …

The introduction of immunotherapy with monoclonal antibodies (mAbs) is a major step
forward for adults and children with B-lineage acute lymphoblastic leukaemia (ALL) and will …

Abstract Evaluation of minimal residual disease (MRD) during first-line treatment and after
salvage therapy is part of the standard management of acute lymphoblastic leukemia (ALL) …